Benign Breast Disease/DCIS Team Project
331
- Srivastava, Sudhir — National Cancer Institute
- Marks, Jeffrey — Duke University Medical Center
- Godwin, Andrew K — University of Kansas Medical Center
- Urban, Nicole — Fred Hutchinson Cancer Research Center
- Li, Christopher — Fred Hutchinson Cancer Research Center
- Skates, Steven — Massachusetts General Hospital
- Cairns, Paul — Fox Chase Cancer Center
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Engstrom, Paul — Fox Chase Cancer Center
A. Paul Cairns (DNA Methylation Sensitivity in IBC) MAL RASSF IA CTGF HIN1 APC RAR GSTP1 IGFBP3 GOS2 B. Andrew Godwin (Protein Biomarker) C. Indra Poola (Protein Biomarker) MMP-1 CEA CAM6 HYAL-1 D. Nicole Urban CAV-1 (Caveolin 1) FN-1 (fibronectin) COL1A1 TIMP4 SPP1 (osteopontin) S100A7 (Psoriasin) MMP10 MMP12
Proteomics
Other, Specify
Other, Specify
Breast and Gynecologic Cancers Research
To identify women diagnosed with atypical ductal hyperplasia (ADH) who are at increased risk of developing invasive breast cancer (IBC) and who might benefit from risk reduction with the use of chemoprevention agents such as Tamoxifen. (Note: A companion protocol will study women with DCIS and their risk for invasive breast cancer.)
Biomarkers expressed in benign breast disease tissue of women who progresse to invasive breast cancer are quantitatively and/or qualitatively different from those expressed in tissue of matched women who do not progress to invasive breast cancer. A nested case-control design will be used to determine if available proteomic and methylation biomarkers predict risk for future invasive cancer (IBC). Women with ADH who are disease-free will be matched 2:1 to women with ADH who progress to IBC.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
